Jamie Samath Sells 269 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) CFO Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $590.00, for a total value of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. This represents a 7.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jamie Samath also recently made the following trade(s):

• On Wednesday, January 29th, Jamie Samath sold 94 shares of Intuitive Surgical stock. The stock was sold at an average price of $571.11, for a total value of $53,684.34.
• On Tuesday, December 10th, Jamie Samath sold 270 shares of Intuitive Surgical stock. The stock was sold at an average price of $540.15, for a total value of $145,840.50.
• On Friday, November 29th, Jamie Samath sold 188 shares of Intuitive Surgical stock. The shares were sold at an average price of $539.00, for a total value of $101,332.00.
• On Tuesday, November 26th, Jamie Samath sold 108 shares of Intuitive Surgical stock. The shares were sold at an average price of $542.06, for a total value of $58,542.48.

Intuitive Surgical Stock Down 0.7 %

ISRG stock opened at $591.65 on Wednesday. The company’s 50-day simple moving average is $555.91 and its 200-day simple moving average is $515.92. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The firm has a market cap of $210.73 billion, a P/E ratio of 92.30, a PEG ratio of 5.67 and a beta of 1.39.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ISRG shares. Leerink Partners increased their price objective on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. JPMorgan Chase & Co. upped their target price on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company upped their target price on Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Citigroup upped their target price on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently modified their holdings of ISRG. Atala Financial Inc purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $25,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical in the 4th quarter valued at about $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical in the 4th quarter valued at about $28,000. Godsey & Gibb Inc. lifted its stake in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical in the 4th quarter valued at about $31,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.